Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Aav vector-mediated deletion of large mutational hotspot for treatment of duchenne muscular dystrophy

A muscular dystrophy, carrier technology, applied in the fields of genome engineering and genome modification, genome engineering and genome modification of genes in muscles, and can solve the problems of large dystrophin gene sequence, non-delivery, safety issues, etc.

Pending Publication Date: 2021-12-10
DUKE UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Both approaches have serious security issues
Furthermore, these strategies are limited by the inability to deliver the large and complex dystrophin gene sequence

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Aav vector-mediated deletion of large mutational hotspot for treatment of duchenne muscular dystrophy
  • Aav vector-mediated deletion of large mutational hotspot for treatment of duchenne muscular dystrophy
  • Aav vector-mediated deletion of large mutational hotspot for treatment of duchenne muscular dystrophy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0192] dual carrier system

[0193] Conventional CRISPR / Cas9 systems for the treatment of DMD typically include more than one vector ( Figure 6 , Figure 7 ). For example, one vector can encode the Cas9 protein, and a second vector can encode two gRNAs. As another example, one vector can encode a Cas9 protein and a first gRNA, and a second vector can encode a Cas9 protein and a second gRNA.

[0194] A schematic diagram of the experiment using multiple vectors to excise exons 45-55 of mouse dystrophin is shown in image 3 , the results are shown in Figure 4 , Figure 5 and Figure 10 middle. Neonatal mice were treated with the dual vector system via systemic / temporal vein injection. Eight weeks after treatment, tissues were harvested. Such as Figure 4 As shown, PCR and sequencing confirmed the deletion of mutation hotspot exons 45–55. Other results are shown in Figure 10 In , AAV-CRISPR targets a control locus ( Figure 10 , upper panel) or targeting exons 45-5...

Embodiment 2

[0196] Validation of the Dual Vector System Therapy Approach

[0197] The CRISPR-based method of restoring a functional dystrophin gene using the dual vector of Example 1 was additionally validated using immortalized myoblasts isolated from DMD patients. Immortalized myoblasts contain a deletion of exons 48-50, creating an out-of-frame mutation ( Figure 9A ). Patient myoblasts were transfected with the same AAV plasmid as used in the HEK293 in vitro experiments in Example 1.

[0198] Deletion PCR of genomic DNA and cDNA revealed efficient deletion of exons 45-55, which was confirmed by Sanger sequencing ( Figure 9B ). Western blot of cell lysates showed that untreated myoblasts did not produce Dystrophin, whereas transfected myoblasts expressed smaller Dystrophin compared to the positive control, consistent with the loss of hotspots ( Figure 9C ). These results also provide in vitro validation that the dual vector construct can be used to edit human mutations and resto...

Embodiment 3

[0200] Components of an all-in-one carrier

[0201] developed a single-vector CRISPR / Cas9 system for the treatment of DMD ( Figure 6 , Figure 7 ). Advantages of single-vector systems may include: having all necessary editing components on a single vector, ability to increase effective dose, simplification of production of other vectors (single therapeutic agent), muscle-specific promoters (e.g., CK8, Spc512, MHCK7) The use / incorporation, and the ability to target combinations of exons and large-scale deletions (e.g., by altering guide sequences). A schematic diagram of the developed all-in-one vector is shown in Figure 8 middle. The sequences contained in some or all of the all-in-one vectors described herein are shown in Table 1. Figure 12 , Figure 13 and Figure 14 The results of testing these constructs in mdx mice are shown. All-in-one vectors are further detailed in Examples 4-7.

[0202]

[0203]

[0204]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed herein are therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Patent Application Serial No. 62 / 833,760, filed April 14, 2019, which is hereby incorporated by reference in its entirety. [0003] Statement Regarding Federally Funded Research [0004] This invention was made with government support under grant R01AR069085 awarded by the National Institutes of Health. The government has certain rights in this invention. technical field [0005] The present disclosure relates to the fields of gene expression alteration, genome engineering and genome modification of genes using clustered regularly interspaced short palindromic repeat (CRISPR) / CRISPR-associated (Cas) 9-based systems and viral delivery systems. The present disclosure also relates to the field of genome engineering and genome alteration of genes in muscles, such as skeletal and cardiac muscle. Background technique [0006] CRISPR / Cas9-based gene editing systems can b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/52A61K48/00C12N15/11C12N15/85C12N9/22
CPCC12N9/22C12N15/113C12N2310/20C12N2320/32C12N2750/14143C07K14/4708C12N2510/00A61K48/005C12N15/86C12N2800/40C12N15/907C12N15/102A61K48/00C12N15/111
Inventor 查尔斯·A·格斯巴赫卡伦·布拉克拉克杰奎琳·N·罗宾逊-哈姆
Owner DUKE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com